A Chip Stock Gets Checked - Behind the Drop in Intel; and Gilead’s Remdesivir Gets the Green Light
Intel shares plunged after the company reported weak results for its data center group. What’s next for the stock that’s been far underperforming the rest of the semi sector. And Gilead gets FDA approval for remdesivir. We break down the rest of the race for a COVID vaccine. Hosted by Simplecast, an AdsWizz company.…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from CNBC's "Fast Money"
See all episodes →Nvidia Fallout, AI Financing Risk and Apple’s Safe-Haven Surge 11/12/26
Nvidia Shares Sink on New Allegations Against CEO Jensen Huang
CoreWeave Earnings, Nvidia Fallout and Rate Hikes Back on the Table
Similar episodes from other shows
More like CNBC's "Fast Money" →
How the Number One U.S. Semiconductor Company Stumbled
Intel Can’t Stop Cutting
The Chip Business Is Booming. Why Isn’t Intel?
What’s News in Markets: Chip Stocks Clobbered, Retail Rotation, Moderna Makes History
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.